We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Available until 1/1/2021

Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.

Already Have An Account? Log in Now

story of the week
Published in Oncology

Journal Scan / Research · November 05, 2020

Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Extended Therapy for HR+ Early-Stage Breast Cancer Patients

Clinical Cancer Research




This abstract is available on the publisher's site.

Access this abstract now

Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Cancer Research
Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of HR+ Early Stage Breast Cancer Patients for 10 Years of Endocrine Therapy
Clin. Cancer Res 2020 Oct 27;[EPub Ahead of Print], I Noordhoek, K Treuner, H Putter, Y Zhang, J Wong, E Meershoek-Klein Kranenbarg, M Duijm-de Carpentier, CJH van de Velde, CA Schnabel, G Liefers

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading